20 May 2013
Keywords: novartis, b-ms, withdraw, zelmac, application, europe, partner
Article | 07 June 2001
Novartis and partner Bristol-Myers Squibb have suffered a setback withthe withdrawal of their marketing application for Zelmac (tegaserod), a
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 June 2001
8 June 2001
17 May 2013
© 2013 thepharmaletter.com